One of the most common experiences for women pregnant after 35 is navigating conversations about prenatal testing—often beginning in the first trimester. These conversations involve unfamiliar terminology, probabilistic information, and sometimes a significant emotional component. Understanding the landscape of prenatal testing—what the tests are, what they can and cannot determine, and how to use the information—can help make these discussions more navigable.
The goal here is not to advocate for any particular testing decision. Prenatal testing choices are personal, intersecting with individual values, beliefs, circumstances, and preferences. What informed decision-making requires is clarity about the options themselves—clarity that isn’t always provided in the time-pressured context of a prenatal appointment.
For broader context on the prenatal care experience after 35, our overview of what to discuss with your OB during prenatal care after 35 covers the full range of topics that often come up in these conversations.
Why Prenatal Testing Is Often Discussed More After 35
Maternal age is associated with a higher statistical prevalence of chromosomal differences in pregnancies—most notably trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. According to data from the Centers for Disease Control and Prevention, the prevalence of trisomy 21 is statistically higher in pregnancies of women over 35, which is why prenatal genetic screening and testing are routinely discussed in this age group.
It’s important to provide context alongside statistics: the majority of pregnancies in women over 35 are chromosomally typical, and statistical risk is population-level information that says nothing definitive about any individual pregnancy. The purpose of prenatal testing is to provide individual pregnancy-specific information, not to confirm a statistical assumption.
Screening Tests vs. Diagnostic Tests: A Critical Distinction
This distinction is fundamental to understanding prenatal testing, yet it’s frequently blurred in the way test results are communicated.
Screening Tests
Screening tests assess the probability that a chromosomal difference is present—they do not provide a definitive diagnosis. A “positive” or “high-risk” screening result means increased probability; it does not mean the condition is present. A “negative” or “low-risk” result means lower probability; it does not mean a condition is definitively absent. Common first-trimester screening includes the combined first-trimester screen (cell-free DNA/NIPT, nuchal translucency ultrasound, and blood biochemistry markers).
Diagnostic Tests
Diagnostic tests—chorionic villus sampling (CVS) and amniocentesis—analyze fetal cells directly and can provide definitive chromosomal information. They are invasive procedures that carry small but real procedural risks (risk of pregnancy loss), which is why they are not universally offered but rather are options for women who want diagnostic certainty—whether because of a high-risk screening result, personal history, or informed preference.
Cell-Free DNA Testing (NIPT): What It Can and Cannot Tell You
Cell-free DNA testing (also called non-invasive prenatal testing, or NIPT) analyzes fragments of fetal DNA that circulate in maternal blood. It has become widely used because it’s non-invasive (a simple blood draw from the mother), can be performed from about 10 weeks’ gestation, and has high sensitivity and specificity for the most common chromosomal differences (trisomies 21, 18, and 13 and sex chromosome differences).
However, NIPT is a screening test, not a diagnostic test. A “high-risk” NIPT result requires confirmation through diagnostic testing (CVS or amniocentesis) before clinical decisions can be made. Additionally, NIPT has higher false-positive rates in younger, lower-risk populations, which is worth understanding even when testing in women over 35.
NIPT is also increasingly being used to screen for a broader range of chromosomal differences and some single-gene disorders, though the evidence base for these expanded panels is less robust and the interpretation of results more complex. Genetic counseling is valuable before and after any prenatal genetic testing, particularly with expanded panels.
First-Trimester Combined Screening
The first-trimester combined screen combines several elements—a nuchal translucency measurement (an ultrasound assessment of fluid at the back of the fetal neck), maternal blood levels of two proteins (PAPP-A and free beta-hCG), and maternal age—to calculate a risk probability for certain chromosomal differences. This approach has a detection rate and false-positive rate that varies depending on specific factors but provides useful probabilistic information without the procedural risk of diagnostic testing.
Understanding that first-trimester combined screening provides a probability rather than a diagnosis is important for processing results—particularly a “high-risk” result, which warrants further discussion with your healthcare team about next steps and options.
Invasive Diagnostic Testing: CVS and Amniocentesis
Chorionic villus sampling (CVS), typically performed between weeks 10–13, and amniocentesis, typically performed after week 15, are the two diagnostic tests that provide definitive chromosomal information. CVS involves sampling placental tissue; amniocentesis involves sampling amniotic fluid containing fetal cells.
Both procedures carry a small risk of pregnancy loss—modern estimates vary, but many experienced centers report risks in the range of 0.1–0.5% for amniocentesis and somewhat higher for CVS, though operator experience significantly affects risk. Discussing these procedures with a maternal-fetal medicine specialist (perinatologist) who performs them regularly can provide more individualized risk assessment.
Decisions about whether to pursue diagnostic testing are deeply personal and involve weighing the value of diagnostic certainty against procedural risk. Genetic counseling can be invaluable for processing these decisions without feeling rushed.
Our article on emotional wellbeing during pregnancy after 35 addresses the emotional dimensions of receiving and processing prenatal testing information, which can be a significant source of stress during pregnancy.
The Role of Genetic Counseling
Genetic counselors are specialized healthcare professionals trained to help individuals and families understand genetic information, interpret test results, and navigate decision-making around genetic testing. Access to genetic counseling before prenatal testing (to choose the right test and set realistic expectations) and after results (to interpret what they mean and discuss options) can significantly improve the experience of navigating prenatal testing.
If your prenatal care setting doesn’t automatically offer genetic counseling, it’s worth asking for a referral—particularly before expanded NIPT panels or if you receive a high-risk screening result.
Frequently Asked Questions
Is prenatal genetic testing required after 35?
No. Prenatal genetic testing is offered and recommended for discussion—it is not mandatory. Decisions about testing are personal and should be informed by individual values, what you would do with the information, and your healthcare provider’s guidance. Some women find that testing provides reassurance; others prefer not to test. Both are valid choices when made with adequate information.
What happens if a prenatal test result is high-risk?
A high-risk result from a screening test (like NIPT or first-trimester combined screen) indicates elevated probability of a chromosomal difference—it does not confirm a diagnosis. The typical next steps involve consultation with a maternal-fetal medicine specialist, genetic counseling, and discussion of whether to proceed with diagnostic testing (CVS or amniocentesis) for definitive information. There is no requirement to make immediate decisions, and taking time to discuss with your healthcare team and, if relevant, your partner is entirely appropriate.
Can prenatal tests detect all chromosomal conditions?
Current prenatal tests—both screening and diagnostic—focus primarily on specific, more common chromosomal differences. Standard chromosomal analysis through CVS or amniocentesis detects large chromosomal abnormalities but does not identify all possible genetic conditions. More comprehensive testing options (chromosomal microarray, whole exome sequencing) are available in some contexts but involve additional complexity in interpretation. Genetic counseling is particularly valuable when considering these expanded options.
When should I discuss prenatal testing with my provider?
Ideally, prenatal testing options should be discussed early in pregnancy—ideally in the first trimester, as some tests are time-sensitive. If you haven’t yet had this conversation and are in your first trimester, raising it at your next appointment or contacting your provider’s office to schedule time specifically for this discussion is reasonable. If possible, a preconception appointment that includes discussion of testing options can help reduce time pressure once pregnancy is confirmed.
Key Takeaways
- Prenatal testing is routinely discussed for women pregnant after 35 due to the statistical association between maternal age and chromosomal differences; however, the majority of pregnancies in this age group are chromosomally typical.
- Screening tests (including NIPT and first-trimester combined screen) assess probability—they provide risk estimates, not diagnoses, and high-risk results require follow-up with diagnostic testing before conclusions can be drawn.
- Diagnostic tests (CVS and amniocentesis) provide definitive chromosomal information but involve procedural risk; decisions about whether to pursue them involve weighing the value of diagnostic certainty against procedural risks.
- Genetic counseling before and after prenatal testing can significantly improve comprehension of results and support more informed, less anxious decision-making.
- Prenatal testing is never mandatory—decisions are personal and should reflect your individual values and what you would do with the information provided.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.